Facial myoclonus manifests as episodic and recurrent involuntary twitching of the facial muscles, also customarily called facial twitching. According to statistics, the prevalence of this disease is between 6/400,000 and 180/100,000, and the disease mostly starts in adulthood, with the most incidences between 30 and 40 years old, and there is no significant difference between men and women in terms of gender. The treatment of facial spasm 1, there is no special medicine. The only effective treatment is botulinum toxin injection, which is used to close the main trunk or branches of the facial nerve, causing partial or complete paralysis of the facial muscles and then stopping the facial muscle spasm, but the effect only lasts 3-6 months, and repeated injections may cause permanent facial paralysis, so it is mostly used for patients with simple blepharospasm or unwilling to undergo surgery. These methods often result in facial muscle paralysis or partial paralysis, such as drug closure, percutaneous puncture facial nerve radiofrequency thermal coagulation, combing of facial nerve, branch severing, and intracranial extrusion. At present, it is rarely used. In 1967, Professor Jennatta of the United States pioneered microvascular decompression for the treatment of facial myospasm, and since the 1980s, this procedure has become the preferred method for the treatment of facial myospasm internationally, with an overall cure rate of 82-99% and a recurrence rate of 1-5%. The specific method is: the skull is opened behind the affected ear, a 2.0 cm bone hole is drilled, the ectopic blood vessels compressing the facial nerve root are probed and stripped under the microscope, and the facial muscle twitching disappears or gradually disappears by isolating with teflon face pads to eliminate the cause of facial muscle spasm.